Company intelligence / Profile preview
Nanjing Nuowei Biotechnology
Nanjing, Jiangsu Sheng, Chinametaflamm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Nanjing Nuowei Biotechnology is a private Chinese biotech company focused on developing oncolytic virus therapies and recombinant polypeptides for the treatment of various cancers, particularly solid tumors. Its lead asset NV-A01 is in Phase 1 for advanced malignant solid neoplasms. Other pipeline assets target liver, pancreatic, colonic, and stomach cancers at earlier stages. No clinical efficacy results have been published as of the latest update.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virusRecombinant polypeptide
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Nanjing Nuowei Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanjing Nuowei Biotechnology.